Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Vivos Therapeutics (VVOS) Shares Outstanding (Diluted Average) (2022 - 2025)

Historic Shares Outstanding (Diluted Average) for Vivos Therapeutics (VVOS) over the last 4 years, with Q3 2025 value amounting to $11.0 million.

  • Vivos Therapeutics' Shares Outstanding (Diluted Average) rose 6573.03% to $11.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.0 million, marking a year-over-year increase of 6573.03%. This contributed to the annual value of $5.0 million for FY2024, which is 31167.49% up from last year.
  • Latest data reveals that Vivos Therapeutics reported Shares Outstanding (Diluted Average) of $11.0 million as of Q3 2025, which was up 6573.03% from $9.1 million recorded in Q2 2025.
  • Vivos Therapeutics' 5-year Shares Outstanding (Diluted Average) high stood at $21.2 million for Q2 2022, and its period low was $849446.0 during Q3 2022.
  • Moreover, its 4-year median value for Shares Outstanding (Diluted Average) was $2.8 million (2024), whereas its average is $5.2 million.
  • In the last 5 years, Vivos Therapeutics' Shares Outstanding (Diluted Average) plummeted by 9436.15% in 2023 and then surged by 45253.92% in 2024.
  • Over the past 4 years, Vivos Therapeutics' Shares Outstanding (Diluted Average) (Quarter) stood at $920592.0 in 2022, then soared by 32.46% to $1.2 million in 2023, then skyrocketed by 311.67% to $5.0 million in 2024, then surged by 118.4% to $11.0 million in 2025.
  • Its Shares Outstanding (Diluted Average) was $11.0 million in Q3 2025, compared to $9.1 million in Q2 2025 and $8.6 million in Q1 2025.